Nature Reviews Endocrinology , 19(1), 1-15
It did stress the importance of reporting suspected side effects and adverse incidents to the Yellow Card scheme, adding that it "engages regularly with the MHRA and disseminates information on drug safety to healthcare professionals, including recent MHRA guidance on the safe use of GLP-1 medicines"
So they have it all in black and white, but we can put that link
People are watching life-changing outcomes, but there is one big question
Semaglutide is an FDA-approved medication with clinical evidence supporting significant weight loss, especially for those with a higher BMI or trouble with appetite control
After analysis, it was suggested by the researchers that the peptide did not directly impact a generalized motor activation, instead it may have potential selective pharmacological impact that may stimulate the central nervous system, mainly the melanocortin receptor activities, which might result in elevated sexual arousal